| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439256 | European Journal of Cancer | 2018 | 7 Pages |
Abstract
We describe the outcome of the largest cohort of AYA patients treated in phase I trials. A subgroup of these patients demonstrates benefit, with several durable responses beyond 2 years. A sizeable proportion of AYA patients have cancer syndromes, significant family history or somatic molecular aberrancies which may influence novel therapeutic treatment options.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Raghav Sundar, Terri McVeigh, David Dolling, Ann Petruckevitch, Nikolaos Diamantis, Joo Ern Ang, Maxime Chenard-Poiriér, Dearbhaile Collins, Joline Lim, Malaka Ameratunga, Khurum Khan, Stan B. Kaye, Udai Banerji, Juanita Lopez, Angela J. George,